Drug Profile
Granisetron intranasal - Athenex
Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Athenex
- Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chemotherapy-induced nausea and vomiting
Most Recent Events
- 12 Sep 2023 Discontinued - Phase-I for Chemotherapy-induced nausea and vomiting in Hong Kong (Intranasal)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Chemotherapy-induced-nausea-and-vomiting in Hong Kong (Intranasal)
- 15 Dec 2015 Phase-I clinical trials in Chemotherapy induced nausea and vomiting in Hong Kong (Intranasal)